ReviewCancers2020
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Abdominal Bloating Following a Diagnosis of Aplastic Anemia: Correlation or Red Herring?Journal of the advanced practitioner in oncology · 2025Article
- Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol.Radiology and oncology · 2024Article
- Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.World journal of oncology · 2024Article
- Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023).Frontiers in immunology · 2024Article
- Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.Cancer biology & therapy · 2023Article
- Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy: A Case Report and Review of the Literature.Journal of clinical and translational hepatology · 2022Article
- Review
- [Emphasis on the treatment of biliary liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Novel Nitric Oxide Donor Dinitroazetidine-Coumarin Hybrids as Potent Anti-Intrahepatic Cholangiocarcinoma Agents.Molecules (Basel, Switzerland) · 2022Article
- CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression.Bioengineered · 2022Article
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors HarboringCancer discovery · 2022Article
- Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.RSC medicinal chemistry · 2021Review
- Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review.Journal of clinical and translational hepatology · 2021Review
- Review
- Molecular Pathogenesis and Regulation of theCancers · 2021Article
- Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.Medicina (Kaunas, Lithuania) · 2021Review
- Complex Liver Resections for Intrahepatic Cholangiocarcinoma.Journal of clinical medicine · 2021Article
- Research Progress of Biliary Tract Cancers.Cancers · 2021Article
- Role of Intraductal RFA: A Novel Tool in the Palliative Care of Perihilar Cholangiocarcinoma.Visceral medicine · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinomas (CCAs) comprise of a heterogeneous group of cancers arising in the biliary tract (intrahepatic or iCCA, perihilar or pCCA and distal or dCCA; the latter are known under the collective term of eCCA), each subtype having its own particularities in carcinogenesis, management and prognosis. The increasing incidence in recent decades, limited treatment options and high mortality rates, even in the early stages, have led to an imperious need for more in-depth understanding and development of tailored treatments for this type of aggressive tumour. The wide use of molecular profiling has increased the understanding of biology and identified key molecular drivers, for example,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.